ストックスクリーナーアプリを入手
19.44
2.32%
0.44
アフターアワーズ：
19.44
前日終値:
$19.00
開ける：
$19.01
24時間の取引高:
151.40K
Relative Volume:
0.45
時価総額：
$1.07B
収益：
$29.71M
当期純損益:
$-69.15M
株価収益率:
-37.89
EPS:
-0.513
ネットキャッシュフロー:
$-52.28M
1週間 パフォーマンス:
+4.52%
1か月 パフォーマンス:
+11.92%
6か月 パフォーマンス:
+52,158%
1年 パフォーマンス:
+52,158%
1日の値動き範囲:
$18.75
$19.92
1週間の範囲:
$17.95
$20.24
52週間の値動き範囲:
$14.72
$29.16
Aktis Oncology Inc Stock (AKTS) Company Profile
Compare AKTS vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AKTS
Aktis Oncology Inc
|
19.44 | 1.05B | 29.71M | -69.15M | -52.28M | -0.513 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Aktis Oncology Inc Stock (AKTS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-09 | 開始されました | H.C. Wainwright | Buy |
| 2026-02-03 | 開始されました | BofA Securities | Buy |
| 2026-02-03 | 開始されました | JP Morgan | Overweight |
| 2026-02-03 | 開始されました | Leerink Partners | Outperform |
| 2026-02-03 | 開始されました | TD Cowen | Buy |
| 2024-01-04 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2023-09-06 | ダウングレード | B. Riley Securities | Buy → Neutral |
| 2023-01-24 | 開始されました | B. Riley Securities | Buy |
| 2021-02-02 | 繰り返されました | Craig Hallum | Buy |
| 2021-01-15 | 繰り返されました | Craig Hallum | Buy |
| 2019-09-18 | ダウングレード | Northland Capital | Outperform → Market Perform |
| 2019-07-10 | アップグレード | Northland Capital | Market Perform → Outperform |
| 2019-05-13 | 繰り返されました | Craig Hallum | Buy |
| 2019-02-05 | 繰り返されました | Craig Hallum | Buy |
| 2019-02-05 | ダウングレード | Northland Capital | Outperform → Market Perform |
| 2018-12-18 | 開始されました | Craig Hallum | Buy |
| 2018-11-30 | 開始されました | Lake Street | Buy |
| 2018-06-22 | 開始されました | Loop Capital | Buy |
| 2018-02-09 | 開始されました | Drexel Hamilton | Buy |
すべてを表示
Aktis Oncology Inc (AKTS) 最新ニュース
William Blair Initiates Aktis Oncology(AKTS.US) With Buy Rating - Moomoo
AKTS: AKY-2519 advances in Phase I-B trials for mCRPC and B7H3-expressing tumors, with key data ahead - TradingView
Top Cybin (HELP) Competitors 2026 - MarketBeat
Aktis initiates phase 1b trial of AKY-2519 in prostate cancer - Investing.com
Aktis opens prostate cancer study as it broadens AKY-2519 testing - Stock Titan
Aktis Oncology Initiates Phase 1b Clinical Trial for - GlobeNewswire
UCB strikes up to $2.2B Candid deal, spotlighting Two River and Vida - Stock Titan
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
This Hyperfine Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Wednesday - Sahm
William Blair Initiates Aktis Oncology(AKTS.US) With Buy Rating, Announces Target Price $32 - Moomoo
William Blair Initiates Aktis Oncology at Outperform - Moomoo
Aktis Oncology: 'Buy' Based On Radiotherapeutic Isotope Design For Broad Targeting (AKTS) - Seeking Alpha
Massachusetts biotech IPOs surge after years of drought - The Business Journals
Aktis Oncology (AKTS) Valuation Check After A Recent 40% One Month Share Price Jump - Yahoo Finance
Aktis Oncology prices IPO at $18 per share - MSN
Economics Weekly: Capacity Growth—It’s Different This Time - William Blair
Analysts Are Bullish on Top Healthcare Stocks: Aktis Oncology, Inc. (AKTS), Intuitive Surgical (ISRG) - The Globe and Mail
Aktis Oncology to Present Clinical Data on AKY-2519 Targeting B7-H3 at 2026 ASCO Annual Meeting - Quiver Quantitative
Two ASCO posters give first look at how Aktis cancer drug moves in tumors - Stock Titan
Aktis Oncology Announces Presentation of First Clinical Imaging and Dosimetry Data for AKY-2519 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting - ChartMill
Is Aktis (AKTS) stock forming a squeeze pattern (Buying Pressure) 2026-04-18Expert Momentum Signals - Cổng thông tin điện tử tỉnh Tây Ninh
Wall Street Analysts Predict a 74.73% Upside in Aktis (AKTS): Here's What You Should Know - Yahoo Finance
Aktis Oncology appoints Glenn Gormley to board of directors By Investing.com - Investing.com India
Director at Aktis Oncology (NASDAQ: AKTS) awarded 37,866 stock options - Stock Titan
Aktis Oncology (AKTS) director Glenn Gormley files initial insider Form 3 - Stock Titan
Veteran pharma leader Glenn Gormley joins Aktis Oncology (AKTS) board as director - Stock Titan
Glenn Gormley Joins Aktis Oncology Board of Directors to Support Cancer Treatment Initiatives - geneonline.com
Aktis Oncology appoints Glenn Gormley to board of directors - Investing.com
Aktis Oncology Appoints Industry Research and Development Veteran Glenn Gormley, MD, PhD to its Board of Directors - GlobeNewswire
Glenn Gormley Net Worth (2026) - GuruFocus
H.C. Wainwright Raises its Price Target on Aktis Oncology (AKTS) to $33 - Insider Monkey
5 Healthcare Stocks Insiders Are Buying - Insider Monkey
Biopharma IPOs Had Their Best Showing In More Than A Year In Q1 - Citeline News & Insights
AMPH Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Aktis Oncology, Inc.: Fundamental Analysis and Financial Ratings | AKTS | US01021M1045 - marketscreener.com
Aktis Oncology: Accelerated Pipeline Progress and High-Value Clinical Catalysts Underpin Buy Rating and $34 Target - TipRanks
Aktis Oncology (AKTS) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $AKTS - MarketBeat
Aktis Oncology’s AKY-2519 gains IND approvals - BioWorld MedTech
H.C. Wainwright raises Akoustis Technologies price target on pipeline progress - Investing.com Canada
AKTS: Analyst Raises Price Target, Maintains 'Buy' Rating | AKTS Stock News - GuruFocus
FDA clears Aktis Oncology’s AKY-2519 for phase 1b trial By Investing.com - Investing.com Australia
Aktis Oncology (NASDAQ: AKTS) secures IND clearances and multi-year cash runway - Stock Titan
AKTS: Strong cash position post-IPO and Eli Lilly deal supports clinical pipeline through 2029 - TradingView
Aktis Oncology (NASDAQ: AKTS) outlines miniprotein alpha radiopharma strategy - Stock Titan
Aktis Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Aktis Oncology Gets FDA Clearance for Phase 1 Billion Trial of Tumor Treatment - marketscreener.com
FDA clears Aktis Oncology’s AKY-2519 for phase 1b trial - Investing.com
Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results - The Manila Times
Aktis Oncology Inc (AKTS) 財務データ
収益
当期純利益
現金流量
EPS
0.14%
0.48%
大文字化:
|
ボリューム (24 時間):